STML - ステムライン・セラピュ―ティクス (Stemline Therapeutics Inc.) ステムライン・セラピュ―ティクス

 STMLのチャート


 STMLの企業情報

symbol STML
会社名 Stemline Therapeutics Inc (ステムライン・セラピュ―ティクス)
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 ステムライン・セラピューティクス(Stemline Therapeutics Inc.)は臨床段階のバイオ医薬品会社であり、腫瘍学治療薬の発見・獲得・開発・商用化に従事する。同社は3種類の臨床段階の製品候補である「SL-401」、「SL-701」、「SL-801」を開発する。「SL-401」は血液癌に存在するインターロイキン3受容体(IL-3R)(CD123)に対する標的療法である。「SL-401」は切断ジフテリア毒素ペイロードに組換えにより融合されたIL-3からなる。「SL-701」は免疫系を活性化して腫瘍を攻撃するように設計された免疫療法である。「SL-701」は脳腫瘍に存在するIL-13受容体サブユニットα-2(IL-13Ra2)、エフリンA型受容体2(EphA2)およびスルビビンを含む標的エピトープに対応する合成ペプチドを含む。「SL-801」は輸液1(XPO1)を可逆的に阻害する経口小分子であり、核輸送タンパク質である染色体領域維持1(CRM-1)として知られる。   ステムライン・セラピュ―ティクスは米国のバイオ医薬品メ―カ―。がん幹細胞や腫瘍容積を対象にした新治療薬の発見、取得、開発、商業化に従事。臨床段階の製品候補、「SL-401」と「SL-701」や、前臨床段階候補薬の「SL-801」と「SL-501」を保有する。本社はニューヨーク。   Stemline Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the discovery, acquisition, development, and commercialization of novel therapeutics for oncology indications of unmet medical need. Its clinical stage product candidates include SL-401, SL-801, and SL-701. The SL-401, is a targeted therapy directed to the interleukin-3 receptor (CD123) present on a malignancies. The SL-801, is a novel oral small molecule reversible inhibitor of XPO1, that has demonstrated in vivo and in vitro preclinical activity in a solid and hematologic malignancies. The SL-701, is an immunotherapy designed to activate the immune system to attack tumors. The company was founded by Ivan Bergstein on August 8, 2003 and is headquartered in New York, NY.
本社所在地 750 Lexington Avenue Eleventh Floor New York NY 10022 USA
代表者氏名 Ivan Bergstein イワン・ベルクスタイン
代表者役職名 Chairman of the Board President Chief Executive Officer 取締役会長兼最高経営責任者(CEO)
電話番号 +1 646-502-2310
設立年月日 37834
市場名 NASDAQ Small Cap
ipoyear 2013年
従業員数
url www.stemline.com
nasdaq_url https://www.nasdaq.com/symbol/stml
adr_tso
EBITDA EBITDA(百万ドル) -76.12596
終値(lastsale) 17.115
時価総額(marketcap) 530137843.83
時価総額 時価総額(百万ドル) 497.14940
売上高 売上高(百万ドル) 0.79940
企業価値(EV) 企業価値(EV)(百万ドル) 401.00745
当期純利益 当期純利益(百万ドル) -75.15090
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Stemline Therapeutics Inc revenues decreased 16% to $500K. Net loss increased 24% to $37.3M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Higher net loss reflects General and administrative - Balancing v increase of 51% to $10.8M (expense) Research and development - Balancing val increase of 11% to $21.7M (expense).

 STMLのテクニカル分析


 STMLのニュース

   Why Stemline Therapeutics (STML) Might Surprise This Earnings Season  2020/05/14 13:33:00 Zacks Investment Research
Stemline Therapeutics (STML) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
   Stemline Therapeutics To Go Private In $667M Transaction  2020/05/04 14:16:44 Benzinga
The New York-based oncology-focused, commercial-stage biopharma Stemline Therapeutics Inc (NASDAQ: STML ) ringed in merger Monday with a go-private deal valued at up to $667 million. Stemline said it has entered a definitive agreement to be bought by privately held Italian pharma and diagnostic company Menarini Group. The Stemline Deal Terms The deal terms call for Menarini commencing a tender offer for all outstanding shares of Stemline for a potential consideration of $12.50 per share — $11.50 in upfront cash payment and one non-tradeable Contingent Value Right, or CVR. The CVR will give the holder the right to receive an additional $1 per share in cash upon completion of the first sale … Full story available on Benzinga.com
   Stock Alert: Stemline Stock Climbs 153% In Premarket On Acquisition News  2020/05/04 08:56:00 RTT News
Biopharmaceutical company Stemline Therapeutics Inc. (STML) is currently trading at $12.02, up $7.27 or 153.05% in the pre-market session. The stock has been trading between $3.
   Will Stemline Therapeutics (STML) Report Negative Q1 Earnings? What You Should Know  2020/05/01 16:30:34 Zacks Investment Research
Stemline Therapeutics (STML) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
   The Daily Biotech Pulse: Gilead Kicks Off Coronavirus Drug Trials, Adcom Nod For Lily, FDA Approves Esperion's Lipid-Lowering Adjunctive Combo Therapy  2020/02/27 12:35:07 Benzinga
The following is a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks that hit 52-week highs on Feb. 26.) Co-Diagnostics Inc (NASDAQ: CODX ) Fate Therapeutics Inc (NASDAQ: FATE ) Gilead Sciences, Inc. (NASDAQ: GILD ) Inspire Medical Systems Inc (NYSE: INSP ) (reacted to fourth-quarter results) Mersana Therapeutics Inc (NASDAQ: MRSN ) Moderna Inc (NASDAQ: MRNA ) Nevro Corp (NYSE: NVRO ) (announced fourth-quarter results) Oyster Point Pharma Inc (NASDAQ: OYST ) Regeneron Pharmaceuticals Inc (NASDAQ: REGN ) Revolution Medicines Inc (NASDAQ: RVMD ) Vir Biotechnology Inc (NASDAQ: VIR ) (announced a collaboration with WuXi Biologics for the development of antibodies to treat COVID-19) Down In The Dumps (Biotech stocks that hit 52-week lows Feb. 26.) ABIOMED, Inc. (NASDAQ: ABMD ) Accelerate Diagnostics Inc (NASDAQ: AXDX ) AcelRx Pharmaceuticals Inc (NASDAQ: ACRX ) Acorda Therapeutics Inc (NASDAQ: ACOR ) AngioDynamics, Inc. (NASDAQ: ANGO ) ANCHIANO THERAP/S ADR (NASDAQ: ANCN ) Aptevo Therapeutics Inc (NASDAQ: APVO ) Auris Medical Holding Ltd (NASDAQ: EARS )(announced publication of results of a study showing anti-epileptic and anti-convulsive activity of betahistine in a mouse model) Blueprint Medicines Corp (NASDAQ: BPMC ) Cumberland Pharmaceuticals, Inc. (NASDAQ: CPIX ) Curis, Inc. (NASDAQ: CRIS ) Enochian Biosciences Inc (NASDAQ: ENOB ) Galectin Therapeutics Inc.
   Why Stemline Therapeutics (STML) Might Surprise This Earnings Season  2020/05/14 13:33:00 Zacks Investment Research
Stemline Therapeutics (STML) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
   Stemline Therapeutics To Go Private In $667M Transaction  2020/05/04 14:16:44 Benzinga
The New York-based oncology-focused, commercial-stage biopharma Stemline Therapeutics Inc (NASDAQ: STML ) ringed in merger Monday with a go-private deal valued at up to $667 million. Stemline said it has entered a definitive agreement to be bought by privately held Italian pharma and diagnostic company Menarini Group. The Stemline Deal Terms The deal terms call for Menarini commencing a tender offer for all outstanding shares of Stemline for a potential consideration of $12.50 per share — $11.50 in upfront cash payment and one non-tradeable Contingent Value Right, or CVR. The CVR will give the holder the right to receive an additional $1 per share in cash upon completion of the first sale … Full story available on Benzinga.com
   Stock Alert: Stemline Stock Climbs 153% In Premarket On Acquisition News  2020/05/04 08:56:00 RTT News
Biopharmaceutical company Stemline Therapeutics Inc. (STML) is currently trading at $12.02, up $7.27 or 153.05% in the pre-market session. The stock has been trading between $3.
   Will Stemline Therapeutics (STML) Report Negative Q1 Earnings? What You Should Know  2020/05/01 16:30:34 Zacks Investment Research
Stemline Therapeutics (STML) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
   The Daily Biotech Pulse: Gilead Kicks Off Coronavirus Drug Trials, Adcom Nod For Lily, FDA Approves Esperion's Lipid-Lowering Adjunctive Combo Therapy  2020/02/27 12:35:07 Benzinga
The following is a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks that hit 52-week highs on Feb. 26.) Co-Diagnostics Inc (NASDAQ: CODX ) Fate Therapeutics Inc (NASDAQ: FATE ) Gilead Sciences, Inc. (NASDAQ: GILD ) Inspire Medical Systems Inc (NYSE: INSP ) (reacted to fourth-quarter results) Mersana Therapeutics Inc (NASDAQ: MRSN ) Moderna Inc (NASDAQ: MRNA ) Nevro Corp (NYSE: NVRO ) (announced fourth-quarter results) Oyster Point Pharma Inc (NASDAQ: OYST ) Regeneron Pharmaceuticals Inc (NASDAQ: REGN ) Revolution Medicines Inc (NASDAQ: RVMD ) Vir Biotechnology Inc (NASDAQ: VIR ) (announced a collaboration with WuXi Biologics for the development of antibodies to treat COVID-19) Down In The Dumps (Biotech stocks that hit 52-week lows Feb. 26.) ABIOMED, Inc. (NASDAQ: ABMD ) Accelerate Diagnostics Inc (NASDAQ: AXDX ) AcelRx Pharmaceuticals Inc (NASDAQ: ACRX ) Acorda Therapeutics Inc (NASDAQ: ACOR ) AngioDynamics, Inc. (NASDAQ: ANGO ) ANCHIANO THERAP/S ADR (NASDAQ: ANCN ) Aptevo Therapeutics Inc (NASDAQ: APVO ) Auris Medical Holding Ltd (NASDAQ: EARS )(announced publication of results of a study showing anti-epileptic and anti-convulsive activity of betahistine in a mouse model) Blueprint Medicines Corp (NASDAQ: BPMC ) Cumberland Pharmaceuticals, Inc. (NASDAQ: CPIX ) Curis, Inc. (NASDAQ: CRIS ) Enochian Biosciences Inc (NASDAQ: ENOB ) Galectin Therapeutics Inc.
   Why Stemline Therapeutics (STML) Might Surprise This Earnings Season  2020/05/14 13:33:00 Zacks Investment Research
Stemline Therapeutics (STML) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
   Stemline Therapeutics To Go Private In $667M Transaction  2020/05/04 14:16:44 Benzinga
The New York-based oncology-focused, commercial-stage biopharma Stemline Therapeutics Inc (NASDAQ: STML ) ringed in merger Monday with a go-private deal valued at up to $667 million. Stemline said it has entered a definitive agreement to be bought by privately held Italian pharma and diagnostic company Menarini Group. The Stemline Deal Terms The deal terms call for Menarini commencing a tender offer for all outstanding shares of Stemline for a potential consideration of $12.50 per share — $11.50 in upfront cash payment and one non-tradeable Contingent Value Right, or CVR. The CVR will give the holder the right to receive an additional $1 per share in cash upon completion of the first sale … Full story available on Benzinga.com
   Stock Alert: Stemline Stock Climbs 153% In Premarket On Acquisition News  2020/05/04 08:56:00 RTT News
Biopharmaceutical company Stemline Therapeutics Inc. (STML) is currently trading at $12.02, up $7.27 or 153.05% in the pre-market session. The stock has been trading between $3.
   Will Stemline Therapeutics (STML) Report Negative Q1 Earnings? What You Should Know  2020/05/01 16:30:34 Zacks Investment Research
Stemline Therapeutics (STML) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
   The Daily Biotech Pulse: Gilead Kicks Off Coronavirus Drug Trials, Adcom Nod For Lily, FDA Approves Esperion's Lipid-Lowering Adjunctive Combo Therapy  2020/02/27 12:35:07 Benzinga
The following is a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks that hit 52-week highs on Feb. 26.) Co-Diagnostics Inc (NASDAQ: CODX ) Fate Therapeutics Inc (NASDAQ: FATE ) Gilead Sciences, Inc. (NASDAQ: GILD ) Inspire Medical Systems Inc (NYSE: INSP ) (reacted to fourth-quarter results) Mersana Therapeutics Inc (NASDAQ: MRSN ) Moderna Inc (NASDAQ: MRNA ) Nevro Corp (NYSE: NVRO ) (announced fourth-quarter results) Oyster Point Pharma Inc (NASDAQ: OYST ) Regeneron Pharmaceuticals Inc (NASDAQ: REGN ) Revolution Medicines Inc (NASDAQ: RVMD ) Vir Biotechnology Inc (NASDAQ: VIR ) (announced a collaboration with WuXi Biologics for the development of antibodies to treat COVID-19) Down In The Dumps (Biotech stocks that hit 52-week lows Feb. 26.) ABIOMED, Inc. (NASDAQ: ABMD ) Accelerate Diagnostics Inc (NASDAQ: AXDX ) AcelRx Pharmaceuticals Inc (NASDAQ: ACRX ) Acorda Therapeutics Inc (NASDAQ: ACOR ) AngioDynamics, Inc. (NASDAQ: ANGO ) ANCHIANO THERAP/S ADR (NASDAQ: ANCN ) Aptevo Therapeutics Inc (NASDAQ: APVO ) Auris Medical Holding Ltd (NASDAQ: EARS )(announced publication of results of a study showing anti-epileptic and anti-convulsive activity of betahistine in a mouse model) Blueprint Medicines Corp (NASDAQ: BPMC ) Cumberland Pharmaceuticals, Inc. (NASDAQ: CPIX ) Curis, Inc. (NASDAQ: CRIS ) Enochian Biosciences Inc (NASDAQ: ENOB ) Galectin Therapeutics Inc.

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 ステムライン・セラピュ―ティクス STML Stemline Therapeutics Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)